scholarly journals Which is the optimal number of random cores to take in MRI/ultrasound fusion-guided biopsy? comparison between 24-core saturation biopsy and a simulated model of 14-core biopsy in a single center cohort

2021 ◽  
Vol 32 ◽  
pp. S110-S111
Author(s):  
Z. Giovanni ◽  
M. Alessandro ◽  
A. Aceti ◽  
G. La Bombarda ◽  
N. Giacomo ◽  
...  
2006 ◽  
Vol 5 (2) ◽  
pp. 313
Author(s):  
J.M. De La Morena ◽  
C. Capitan ◽  
D. Martin ◽  
M. Alvarez ◽  
P. Dominguez ◽  
...  

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 123-123
Author(s):  
Jamie Sungmin Pak ◽  
Philippa J. Cheetham ◽  
Aaron Katz ◽  
Sven Wenske

123 Background: Primary focal cryosurgery (PFC) has emerged as a viable option for local therapy in prostate cancer (PCa), most suitable for patients with clinical stage T1c-T3 disease of any tumor grade in whom potency is not of primary concern and who are not suitable for radical prostatectomy or radiation therapy. Success of 5-year biochemical recurrence (BCR)-free survival, depending on criteria, ranges from 60% to 90% in the literature. We hypothesize that saturation biopsy before PFC leads to lower rates of BCR compared to standard 12-core biopsy. Methods: We compiled a consecutive series of patients who underwent PFC at our institution for localized PCa. Parameters including demographics, PSA levels, and Gleason scores before primary treatment and at time of recurrence were assessed. Biochemical failure was defined by both Phoenix (PD) and Stuttgart (SD) definitions. Chi-square analysis was performed to compare outcomes. Results: One hundred and forty-seven patients underwent PFC at our institution between August 2000 and January 2014. Forty-five patients were excluded due to incomplete follow-up data and/or missing biopsy information. Median follow-up was 40.3 months (0.8-116, IQR 41). Conclusions: Zero of the six patients who underwent a saturation biopsy before PFC experienced biochemical failure or progression. This in contrast to those who underwent a standard 12-core biopsy before PFC, of which 19% experienced biochemical failure by PD and 26% by SD, and 6% underwent progression. This may be due to more informed selection for local therapy and more comprehensive assessment of the extent of tumor for treatment planning. Though these differences were not statistically significant in our study, we believe that our results lay the groundwork for a larger study to assess differences in outcomes after PFC depending on the extent of biopsy before treatment. [Table: see text]


2007 ◽  
Vol 65 (5) ◽  
pp. AB199
Author(s):  
Daniel Sussman ◽  
Carmen R. Gomez-Fernandez ◽  
Afonso C. Ribeiro

2020 ◽  
Vol 45 (12) ◽  
pp. 4150-4159
Author(s):  
Joan C. Vilanova ◽  
Anna Pérez de Tudela ◽  
Josep Puig ◽  
Martijn Hoogenboom ◽  
Joaquim Barceló ◽  
...  

Diagnostics ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 1638
Author(s):  
Geke Litjens ◽  
Christian Gerges ◽  
Yogesh M. Shastri ◽  
Piyush Somani ◽  
Torsten Beyna ◽  
...  

Endoscopic ultrasound (EUS) with fine needle aspiration (FNA) or biopsy (FNB) to diagnose lesions in the gastrointestinal tract is common. Demand for histology sampling to identify treatment-specific targets is increasing. Various core biopsy FNB needles to obtain tissue for histology are currently available, however, with variable (37–97%) histology yields. In this multicenter study, we evaluated performance, safety, and user experience of a novel device (the puncture biopsy forceps (PBF) needle). Twenty-four procedures with the PBF needle were performed in 24 patients with a suspected pancreatic lesion (n = 10), subepithelial lesion (n = 10), lymph node (n = 3), or pararectal mass (n = 1). In 20/24 (83%) procedures, the PBF needle yielded sufficient material for interpretation (sample adequacy). In 17/24 (71%), a correct diagnosis was made with the material from the PBF needle (diagnostic accuracy). All participating endoscopists experienced a learning curve. (Per)procedural technical issues occurred in four cases (17%), but there were no adverse events. The PBF needle is a safe and potentially useful device to obtain an EUS-guided biopsy specimen. As the design of the PBF needle is different to core biopsy FNB needles, specific training will likely further improve the performance of the PBF needle. Furthermore, the design of the needle needs further improvement to make it more robust in clinical practice.


2017 ◽  
Vol 85 (5) ◽  
pp. AB486-AB487
Author(s):  
Lionel S. D'Souza ◽  
Mohamed Barakat ◽  
Praneet Korrapati ◽  
Gil I. Ascunce ◽  
Evin J. McCabe ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document